Aurobindo Pharma arm expands MSD pact, to set up $150-175 million facility
Published on 15/04/2026 04:55 PM
Aurobindo Pharma arm expands MSD pact, to set up $150-175 million facilityAurobindo Pharma unit TheraNym expands CMO deal with MSD, to build 60,000 litre Unit 2 drug substance plant investing $150 to $175 million, stock gains 2.63%.By Navneet Singh April 15, 2026, 4:55:12 PM IST (Published)2 Min ReadAurobindo Pharma Ltd said on Wednesday, April 15, that its subsidiary TheraNym Biologics Pvt. Ltd. has expanded its existing contract manufacturing operations (CMO) agreement with Merck Sharp & Dohme Singapore Trading Pte Ltd by executing an additional product schedule.
The company said that the new schedule builds on the arrangement first announced in May 2024 and pertains to the construction and commissioning of a greenfield drug substance manufacturing facility, referred to as “Unit 2”.
Under the agreement, as per the exchange filing, TheraNym will establish a large-scale mammalian cell culture-based facility with a total bioreactor capacity of 60,000 litres, along with the required downstream purification infrastructure to produce drug substances.
Also Read: Closing bell | Markets surge to near day’s high; Sensex jumps 1,264 points, ₹10 lakh crore added to investor wealth
TheraNym will undertake manufacturing at the facility and supply the products to MSD as per the terms of the arrangement. The company plans to invest around $150–175 million in setting up the facility.
In its Q3 FY26 results, the firm had posted a net profit of ₹909.8 crore, up 7.5% year-on-year from ₹846 crore, inclusive of a one-time cost of ₹65 crore due to a change in the labour code.
Its revenue for the quarter grew 8.4% year-on-year to ₹8,646 crore, compared with ₹7,979 crore in the same period last year, supported by growth in Europe and the ARV (Antiretroviral drugs) segment.
Shares of Aurobindo Pharma Ltd ended higher on April 15, with the stock settling at ₹1,375.00 on the NSE, up ₹35.20 or 2.63% for the day. The stock has gained 24% over the past six months.
Also Read: Retail flows stay resilient as MF AUM falls 10.1% MoM in March: Motilal OswalContinue ReadingTagsAurobinda Pharmadrugshare market today